134 related articles for article (PubMed ID: 38198799)
1. Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
Loh Z; Ashby M; Van Veldhuizen E; Li W; Chee A; Aung W; Lavrukhina Y; Mason G; Pelly T; Nedumannil R; Kosciejew S; Mokoonlall M; Lim J; Calov G; Butler L; Hillebrand P; Beekman A; Rathnasekara GK; Raj S; Zhang C; Yao Y; Iland H; Grigg A
Br J Haematol; 2024 May; 204(5):1732-1739. PubMed ID: 38198799
[TBL] [Abstract][Full Text] [Related]
2. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
5. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
[TBL] [Abstract][Full Text] [Related]
7. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
Aznab M; Rezaei M
Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
9. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Guo M; Zhao Q; Fan S; Wu Z; Lin L; Chen H; Gao Y; Hai X
Br J Clin Pharmacol; 2021 Oct; 87(10):4020-4026. PubMed ID: 33638869
[TBL] [Abstract][Full Text] [Related]
11. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
12. Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Jiang Y; Ji L
J Int Med Res; 2020 Sep; 48(9):300060520959487. PubMed ID: 32993392
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
14. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
18. Poison With a Purpose: A Case Report on Arsenic Cardiotoxicity and Obesity.
Nachtigal EA; Doan TN
Cureus; 2022 Dec; 14(12):e33185. PubMed ID: 36726885
[TBL] [Abstract][Full Text] [Related]
19. Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells.
Mirjalili S; Khaleghian A; Kalalinia F
Biometals; 2021 Oct; 34(5):1067-1080. PubMed ID: 34255251
[TBL] [Abstract][Full Text] [Related]
20. Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury.
Gao C; Fan S; Hostetter TH; Wang W; Li J; Guo M; Zhou J; Hai X
Br J Clin Pharmacol; 2019 Apr; 85(4):849-853. PubMed ID: 30677159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
